Major drugmakers offer big discount on blood thinner Eliquis

Bristol Myers Squibb and Pfizer have launched a direct-to-patient program for their blockbuster blood thinner Eliquis, offering a 40% discount to uninsured or underinsured patients, reducing the monthly cost to $346. This initiative, aimed at expanding access for the nation's top-prescribed oral anticoagulant which generated over $3 billion in Q4 FY24 sales, reflects a growing industry trend where major pharmaceutical companies like Eli Lilly and Novo Nordisk are increasingly bypassing traditional insurance channels with self-pay options for high-demand drugs, potentially reshaping drug distribution and pricing dynamics.

Analysis

Bristol Myers Squibb (BMY) and Pfizer (PFE) have initiated a strategic shift in their distribution model for Eliquis, their blockbuster oral anticoagulant, by launching a direct-to-patient program. This initiative provides a 40% discount to uninsured or cash-paying patients, reducing the monthly cost from $606 to $346. The move is significant given Eliquis's market leadership as the top-prescribed oral anticoagulant in the U.S. and its substantial revenue contribution, which exceeded $3 billion in the fourth quarter of fiscal 2024. While the lower price point could pressure margins on sales through this channel, it aims to expand the total addressable market and bolster patient retention. This strategy mirrors recent actions by Eli Lilly and Novo Nordisk for their high-demand diabetes and weight-loss drugs, indicating a broader industry trend toward disintermediating traditional insurance and pharmacy benefit manager channels. The positive 1.85% stock movement for BMY suggests investor optimism that increased volume and direct patient relationships will outweigh the per-unit price reduction, potentially reshaping competitive dynamics in the pharmaceutical sector.

Key Decisions for Investors

• Investors in Bristol Myers Squibb and Pfizer should closely monitor future earnings reports for data on patient uptake through the new direct-to-consumer channel to assess if increased volume from previously unaddressed patients can offset the margin compression from the 40% discount.
• This direct-to-patient strategy represents a growing trend among major pharmaceutical firms to bypass traditional intermediaries; portfolios should be evaluated to identify companies that are effectively adapting to this evolving distribution landscape versus those that remain heavily dependent on conventional insurance-based sales models.
• While the program enhances Eliquis's competitive positioning by improving access, it introduces new operational risks related to direct shipping and patient management, which should be considered as a potential factor in execution and scalability.